Literature DB >> 12720119

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Robert A Kyle1, Steven P Treon, Raymond Alexanian, Bart Barlogie, Magnus Björkholm, Madhav Dhodapkar, T Andrew Lister, Giampaolo Merlini, Pierre Morel, Marvin Stone, Andrew R Branagan, Véronique Leblond.   

Abstract

This presentation represents consensus recommendations on prognostic markers and criteria to initiate therapy in patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. The panel recommended that initiation of therapy should not be based on the IgM level per se since this may not correlate with the clinical manifestations of WM. The consensus panel agreed that initiation of therapy was appropriate for patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due to anemia, or weight loss. The presence of progressive, symptomatic lymphadenopathy or splenomegaly provide additional reasons to begin therapy. The presence of anemia with a hemoglobin value of <or= 10 g/dL or a platelet count < 100 x 10(9)/L due to marrow infiltration also justifies treatment. Certain complications such as hyperviscosity syndrome, symptomatic sensorimotor peripheral neuropathy, systemic amyloidosis, renal insufficiency, or symptomatic cryoglobulinemia may also be indications for therapy. Recommendations for follow-up of watch-and-wait patients are that those with monoclonal gammopathy of undetermined significance (MGUS) should have serum protein electrophoresis repeated each year. Patients with asymptomatic (smoldering) macroglobulinemia should be evaluated every 6 months. Regarding prognostic markers, hemoglobin and beta(2)-microglobulin levels at diagnosis are important prognostic markers in WM: they influence the timing of treatment and survival. Age is a consistently important prognostic factor for survival. However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720119     DOI: 10.1053/sonc.2003.50038

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  59 in total

1.  Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

Authors:  Onyemaechi N Okolo; Ariel C Johnson; Seongseok Yun; Stacy J Arnold; Faiz Anwer
Journal:  Immunotherapy       Date:  2017-08-03       Impact factor: 4.196

2.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

3.  Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.

Authors:  Efstathios Kastritis; Marie-Christine Kyrtsonis; Pierre Morel; Maria Gavriatopoulou; Evdoxia Hatjiharissi; Argirios S Symeonidis; Amalia Vassou; Panagiotis Repousis; Sossana Delimpasi; Anastasia Sioni; Evrydiki Michalis; Michail Michael; Elina Vervessou; Michael Voulgarelis; Costantinos Tsatalas; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

4.  Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Authors:  Robert A Kyle; Dirk R Larson; Ellen D McPhail; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Prashant Kapoor; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2018-04-12       Impact factor: 7.616

Review 5.  Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Authors:  Meletios A Dimopoulos; Efstathios Kastritis; Roger G Owen; Robert A Kyle; Ola Landgren; Enrica Morra; Xavier Leleu; Ramón García-Sanz; Nikhil Munshi; Kenneth C Anderson; Evangelos Terpos; Irene M Ghobrial; Pierre Morel; David Maloney; Mathias Rummel; Véronique Leblond; Ranjana H Advani; Morie A Gertz; Charalampia Kyriakou; Sheeba K Thomas; Bart Barlogie; Stephanie A Gregory; Eva Kimby; Giampaolo Merlini; Steven P Treon
Journal:  Blood       Date:  2014-07-15       Impact factor: 22.113

6.  Welcome to the 9th Volume of Immunotherapy.

Authors:  Sonia Mannan
Journal:  Immunotherapy       Date:  2017-01       Impact factor: 4.196

7.  Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.

Authors:  Stephanie Guidez; Julien Labreuche; Elodie Drumez; Loic Ysebaert; Jana Bakala; Caroline Delette; Bénédicte Hivert; Caroline Protin; Hervé Declercq; Mélanie Verlay; Jean Pierre Marolleau; Alain Duhamel; Pierre Morel
Journal:  Blood Adv       Date:  2018-11-27

8.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

9.  Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

Authors:  Steven P Treon; Jacob D Soumerai; Zachary R Hunter; Christopher J Patterson; Leukothea Ioakimidis; Brad Kahl; Michael Boxer
Journal:  Blood       Date:  2011-05-12       Impact factor: 22.113

10.  Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Authors:  L Xu; Z R Hunter; G Yang; Y Cao; X Liu; R Manning; C Tripsas; J Chen; C J Patterson; M Kluk; S Kanan; J Castillo; N Lindeman; S P Treon
Journal:  Leukemia       Date:  2014-02-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.